Cansino announced that the daily closing price increase deviation value of the company's stock exceeded 30% for 3 consecutive trading days on August 19, August 20, and August 21, 2026. The company's production and operation are normal, and there have been no major adjustments in the market environment or industry policies; recently, the market is focusing on mRNA technology. The company is promoting the development of related vaccines, therapeutic biological products and delivery systems, and related research and development is currently in the early stages.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.